ReviewEye (London, England)2018
Neuro-ophthalmic side effects of molecularly targeted cancer drugs.
Review in Eye (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Risk of retinal vein occlusions in patients taking systemic tyrosine kinase inhibitors.Eye (London, England) · 2026Article
- Protective Role of Thiamine Pyrophosphate Against Erlotinib-Induced Oxidative and Inflammatory Damage in Rat Optic Nerve.Biomedicines · 2025Article
- Risk of Moderate to Severe Ocular Surface Disease Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A Multicenter Cohort Study.Ophthalmology and therapy · 2025Article
- Advancement in medical treatment for gastrointestinal stromal tumors (GISTs): a ray of hope.Annals of medicine and surgery (2012) · 2025Review
- Drug-Induced Uveitis: Patterns, Pathogenesis and Clinical Implications.Clinical optometry · 2025Review
- Ocular Surface Side Effects of Novel Anticancer Drugs.Cancers · 2024Review
- Probable ponatinib-induced papilledema in a patient with acute lymphocytic leukemia.American journal of ophthalmology case reports · 2023Article
- Enhancing and stabilizing monoclonal antibody production by Chinese hamster ovary (CHO) cells with optimized perfusion culture strategies.Frontiers in bioengineering and biotechnology · 2023Article
- The Role of ROS as a Double-Edged Sword in (In)Fertility: The Impact of Cancer Treatment.Cancers · 2022Review
- Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review.Metabolism open · 2021Article
- Ocular Toxicity of Targeted Anticancer Agents.Drugs · 2021Review
- Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review.Journal of immunotherapy and precision oncology · 2021Review
- Ocular side effects of novel anti-cancer biological therapies.Scientific reports · 2021Article
- Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors.BMC ophthalmology · 2020Article
- Diagnosis and Management of Rare Immune-Related Adverse Events.The oncologist · 2020Article
- Purified human anti-Tn and anti-T antibodies specifically recognize carcinoma tissues.Scientific reports · 2019Article
- Effects of Brain Tumors on Vision in Children.International ophthalmology clinics · 2018Review
- Cabozantinib-Associated Exudative Retinal Detachment and Choroiditis: A Case Report.Journal of current ophthalmologyArticle
- Ocular adverse effects of therapeutic biologics.Therapeutic advances in ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The past two decades has been an amazing time in the advancement of cancer treatment. Molecularly targeted therapy is a concept in which specific cellular molecules (overexpressed, mutationally activated, or selectively expressed proteins) are manipulated in an advantageous manner to decrease the transformation, proliferation, and/or survival of cancer cells. In addition, increased knowledge of the role of the immune system in carcinogenesis has led to the development of immune checkpoint inhibitors to restore and enhance cellular-mediated antitumor immunity. The United States Food and Drug Administration approval of the chimeric monoclonal antibody (mAb) rituximab in 1997 for the treatment of B cell non-Hodgkin lymphoma ushered in a new era of targeted therapy for cancer. A year later, trastuzumab, a humanized mAb, was approved for patients with breast cancer. In 2001, imatinib was the first small-molecule kinase inhibitor approved. The approval of ipilimumab-the first in class immune checkpoint inhibitor-in 2011 serves as a landmark period of time in the resurgence of immunotherapy for cancer. Despite the notion that increased tumor specificity results in decreased complications, toxicity remains a major hurdle in the development and implementation of many of the targeted anticancer drugs. This article will provide an overview of the current cellular and immunological understanding of cancer pathogenesis-the foundation upon which molecularly targeted therapies were developed-and a description of the ocular and neuro-ophthalmic toxicity profile of mAbs, immune checkpoint inhibitors, and small-molecule kinase inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.